Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| GlaxoSmithKline | 2.56% | $469.46K | £88.76B | 48.32% | 77 Outperform | |
| ― | 2.55% | $466.99K | ― | ― | ― | |
| Roche Holding AG | 2.42% | $444.14K | CHF295.18B | 44.93% | 73 Outperform | |
| Bristol-Myers Squibb | 2.35% | $431.25K | $125.45B | 3.91% | 78 Outperform | |
| Yum China Holdings | 2.34% | $430.05K | $20.24B | 10.54% | 78 Outperform | |
| BAE Systems | 2.27% | $416.90K | £62.43B | 65.45% | 61 Neutral | |
| Koninklijke Philips N.V. | 2.14% | $392.73K | €25.29B | 6.87% | 56 Neutral | |
| Spirax Group | 2.12% | $388.47K | £5.83B | 8.15% | 72 Outperform | |
| Thales | 2.11% | $387.22K | €51.63B | 31.49% | 73 Outperform | |
| US Bancorp | 2.10% | $384.62K | $85.50B | 23.72% | 76 Outperform |